A systematic review comparing sex-specific outcomes of prospective clinical trials and subsequent real-world data focusing on systemic treatment options for renal cell cancer
This systematic review enlightens sex-specific gaps in enrollment and cancer outcome, as well as the lack of sex-specific toxicity analyses. Balanced enrollment rates and reporting of sex-specific toxicity should be obligate in evaluations of la/mRCC treatments.
Authors
- Axel S. Merseburger (ORCID: https://orcid.org/0000-0001-6467-3931)
- Lara Franziska Stolzenbach (ORCID: https://orcid.org/0000-0003-2747-4153)
- Nils Gilbert
- Lea Sophie Lütje
- Friederike Praus
- Daniar Osmonov
- Marie Christine Roesch
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1159/000551236
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Eisai
- Astellas Pharma
- Ipsen